Aorfix AAA Stent Graft Body with Aorflex Delivery System SG-HBB-27-96-80-16-A12-22Recalls & reported problems
Lombard Medical Limited · Aorflex AAA Stent Graft Body with Aorflex Delivery System · Class 3 · Implant
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 05055715609210), received between Aug 4, 2015 and Jan 21, 2016 — classified as 2 injuries.
The most frequently reported specific device problem is “Failure to Advance” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
- Failure to Advance1
- Obstruction of Flow1
Patient problems
- Aneurysm2
- Calcium Deposits/Calcification1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
InjuryJan 21, 2016Failure to Advance; Adverse Event Without Identified Device or Use Problem; Failure to Advance; Adverse Event Without Identified Device or Use Problem
THE PATIENT WAS INITIALLY SUPPOSED TO UNDERGO ABDOMINAL EVAR BY THE RIGHT FEMORAL ARTERY APPROACH. NO ABNORMALITIES IDENTIFIED AT PRE-OPERATIVE CT. THE PHYSICIAN ATTEMPTED TO INSERT A MAIN BODY DEVICE ALIGNING WITH THE EGOIST GUIDEWIRE (ASAHI-INTECC). HOWEVER, THE MAIN BODY WAS ENTRAPPED WITH SOMETHING AND WOULD NOT ADVANCE. THEN, HE INSERTED A DRY SEAL (GORE, 18 FR) AS A TRIAL DEVICE AND IT ADVANCED SMOOTHLY WITHOUT PROBLEM. THEREFORE, NOW HE RE-ATTEMPTED TO INSERT THE MAIN BODY AGAIN, BUT IT WOULD NOT ADVANCE. FINALLY, HE ATTEMPTED TO INSERT A DRY SEAL (GORE, 22 FR), BUT THE MAIN BODY WOULD NOT ADVANCE THIS TIME, TOO. ADDITIONAL ACTION TAKEN BY THE PHYSICIAN: HE OBSERVED DAMAGES IN TUNICA INTIMA OF BLOOD VESSELS. THEN, HE ATTEMPTED TO FIX THEM. FOLLOWING IT, HE SWITCHED TO THE EXTERNAL ILIAC ARTERY APPROACH, PALPATED IT AND FOUND THAT IT WAS WITH ENTIRE CIRCUMFERENCE OF CALCIFICATION. HE GAVE UP PERFORMING EVAR AND CHANGED TO VASCULAR PROSTHESIS IMPLANTATION. PROCTOR'S COMMENT: PRE-OPERATIVE CT REVEALED NO ABNORMALITIES. I CANNOT ASSUME THE CAUSE OF THIS TROUBLE. ONE OF POSSIBLE CAUSES MIGHT BE STIFF BLOOD VESSELS OF THE PATIENT (B)(6) 2015 - SINCE THE EVAR SWITCHED TO THE VASCUL
Patient problems: Aneurysm; Calcium Deposits/Calcification
MAUDE report 5382391 ↗InjuryAug 4, 2015Obstruction of Flow
THE ORIGINAL PROCEDURE WAS PERFORMED ON (B)(6) 2015 WHICH WAS COMPLETED WITHOUT ENDOLEAK. THE FOLLOW-UP CT, PERFORMED ONE WEEK AFTER THE ORIGINAL PROCEDURE, SHOWED THAT THE STENT GRAFT PARTIALLY COVERED THE RIGHT RENAL ARTERY, ALTHOUGH IT IS POSSIBLE TO SEE THERE IS CONTRAST AGENT FLOW. ON (B)(6) 2015, THE COMPANY BECAME AWARE THAT A RE-INTERVENTION WAS PERFORMED ON (B)(6) 2015 (10 DAYS AFTER THE INITIAL PROCEDURE) TO IMPLANT A RENAL STENT WHICH SUCCESSFULLY RESOLVED THE PARTIALLY OCCLUDED RENAL ARTERY. DHR REVIEW: A FULL REVIEW OF THE DEVICE HISTORY RECORD FOR THIS DEVICE HAS BEEN CARRIED OUT WITH NO ANOMALIES IDENTIFIED; PRODUCT WAS MANUFACTURED AND RELEASED FOR SALE IN ACCORDANCE WITH SPECIFICATIONS. THERE IS NO INFORMATION TO SUGGEST THAT THE DEVICE HAS NOT MET THE FINAL RELEASE CRITERIA. CASE REVIEW (INCLUDING SIZING SHEET AND SCAN REVIEW WHERE REQUIRED): ORIGINAL EVAR WAS PERFORMED (B)(6) 2015. ON COMPLETION OF THE SURGERY, THE PHYSICIAN WAS AWARE THAT A RENAL STENT MAY BE REQUIRED AT A LATER DATE. THE RIGHT RENAL ARTERY WAS SUSPECTED TO BE PARTIALLY BLOCKED. THE FOLLOW UP CT SCAN PERFORMED ONE WEEK AFTER THE ORIGINAL PROCEDURE CONFIRMED THAT THE STENT GRAFT WAS PARTIALLY COV
Patient problems: Aneurysm
MAUDE report 4975922 ↗
Other System, Endovascular Graft, Aortic Aneurysm Treatment devices
- Endurant® IIs ESBF2814C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls34 deaths254 reports
- Endurant® IIs ESBF3214C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls19 deaths173 reports
- Endurant® IIs ESBF3614C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT1 recall37 deaths214 reports
- Endurant® IIs ESBF2514C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls18 deaths136 reports
- Endurant® IIs ESBF2314C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls9 deaths60 reports
- RelayPro Thoracic Stent-Graft System 28-N4-34-154-34UBolton Medical Inc. · System, Endovascular Graft, Aortic Aneurysm Treatment3 recalls7 reports
- Vela Proximal Endograft System A34-34/C100-O20 VEndologix LLC · System, Endovascular Graft, Aortic Aneurysm Treatment3 deaths152 reports
- Endurant® II ETCF2828C49EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls7 deaths44 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page